Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
Filter by
-
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
Read more -
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
Read more -
Positive results from Harmony Outcomes study of albiglutide published in The Lancet
GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive resul...
Read more -
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis ende...
Read more -
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in ...
Read more -
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issue...
Read more -
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the ...
Read more -
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GlaxoSmithKline plc (GSK) will profile the growing evidence base that supports its broad respirat...
Read more -
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
Read more -
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc (LSE/NYSE: GSK) today received a complete response letter (CRL) from the US F...
Read more -
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
Read more -
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, ...
Read more -
Iain Mackay appointed GSK Chief Financial Officer
GSK today announced that Iain Mackay has been appointed GSK’s next CFO.
Read more -
CHMP recommend Nucala (mepolizumab) for the treatment of severe eosinophilic asthma paediatric patients in Europe
GSK announced that the EMA's CHMP has issued a positive opinion recommending Nucala (mepolizumab)...
Read more -
GSK reports on outcome of the FDA Advisory Committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy
Advisory Committee provide non-binding recommendation for consideration by the FDA
Read more -
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
Multi-year collaboration expected to identify novel drug targets, tackle new subsets of disease a...
Read more -
GSK delivers improvements in sales, margins and cash flow in Q2 2018
Total EPS 9.0p, >100% AER, >100% CER; Adjusted EPS 28.1p, +3% AER, +10% CER
Read more -
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), today announced the transitio...
Read more -
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression th...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
